The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Advances in community oncology: bispecific antibodies and treatment selection in FL
Kim Linton, MBChB, MRCP, PhD, FRCP, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK, discusses key updates in follicular lymphoma (FL) for community practice from SOHO 2026. Prof. Linton highlights the expanding role of community-based bispecific antibody delivery, emphasizing the training and infrastructure needed to safely manage cytokine release syndrome (CRS) and other treatment-related toxicities. She also discusses challenges in treatment sequencing, therapy selection, and the development of predictive biomarkers as the treatment landscape continues to evolve. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
